WHO IS KANE BIOTECH?

PROPRIETARY TECHNOLOGY FOR $20B+ MARKET
Kane Biotech is a biotechnology company focused on becoming a leader in the development of products for wound care and the prevention and removal of bacterial biofilms using it’s DispersinB® technology. Biofilms are a major cause of a number of serious medical problems. They develop on surfaces such as wounds, catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone
costs the United States health care system $20 Billion per year.

INVESTMENT HIGHLIGHTS (NEXT 12 MONTHS)
Chronic wound healing FDA biocompatibility studies completed and clinical study underway
Combat trauma wound technology in development with the US army
Companion animal oral care product test launch

MARKET FOCUS:

WOUND CARE
Biofilms are the major cause of wound care product failure. Current antibiotic treatments are not effective against bacteria in a biofilm, and these bacteria hamper the healing process. DispersinB® destroys the biofilm exposing the bacteria to the antibiotics, thus allowing the antibiotics to kill the bacteria and allowing the wound to heal. The current market for diabetic foot and leg ulcer topical products is a
US$4.1 Billion annually in the U.S. alone.

CATHETER COATINGS
80% of all hospital acquired infections are device related with 50% from urinary and venous catheters. Biofilms are also a major cause of hospital acquired infections. Currently only 35% of the Foley urinary catheters and 20% of venous catheters are coated. Most catheters cause a risk of infection within 3 days, some as quick as 1 day. The current market for urinary and venous catheter coatings is 5M CVC's, 20M Foley urinary catheters and 150M intravascular in the U.S. alone.

Fact Sheet Link

Kane Biotech Awarded Contract by the United States Army to Develop Antibiofilm-Antimicrobial Wound Gel

WINNIPEG, MANITOBA, May 31, 2011
Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has been awarded a contract by the United States Army Dental and Trauma Research Detachment (USADTRD) to develop an antibiofilm-antimicrobial wound gel formulation comprising Kane Biotech's DispersinB(R) antibiofilm enzyme and the US Army's KSL-W antimicrobial peptide. The awarding of this contract is part of a continued collaborative effort in accordance with the previously announced Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) signed with the U.S. Army's Walter Reed Army Institute of Research.

The scope of work includes: (i) formulation of the wound gel; (ii) standardization of sterilization and methods to determine the concentrations of both the active and inactive ingredients; (iii) determination of antibiofilm and antimicrobial activity against wound infection-associated bacteria; and (iv) comparison of antibiofilm-antimicrobial activity of the wound gel with that of selected commercially available antimicrobial wound gels.

"We are honored to continue our work with the US Army Dental and Trauma Research Detachment to help develop their combat wound gel formulation and to have our DispersinB technology play a key role in biofilm impaired wound healing," stated Gord Froehlich, President and CEO of Kane Biotech Inc. "The deleterious effect of bacterial infection on wound healing has been known for decades and the control of biofilm-embedded and antibiotic resistant bacteria are recognized as critical factors in wound care management."

About Walter Reed Army Institute of Research

The Walter Reed Army Institute of Research has an overarching mission to conduct biomedical research focused on the health and medical readiness of US military personnel, to ensure that America's war-fighters are equipped with the most effective medical defenses and treatments relative to international health threats. The WRAIR fulfills its mission by conducting innovative basic and applied biomedical research and development of technologies to: (i) prevent, diagnose, and treat infectious diseases; (ii) treat and transport combat casualties; (iii) prevent and minimize operational stress and health hazards; and (iv) prevent and treat casualties from biological and chemical agents.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

SOURCE: Kane Biotech Inc.

Kam Thindal 604-566-9236 office 604-488-9875 mobile kam@puread.ca Kane Biotech Inc. Gord Froehlich President & Chief Executive Officer 204-477-7592 204-453-1314(FAX) ir@kanebiotech.com www.kanebiotech.com